PCI Biotech receives US Orphan Drug Designation for fimaporfin in the treatment of bile duct cancer (cholangiocarcinoma)

Posted on Oct 5, 2017

Oslo, 4 October 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead product candidate, fimaporfin, for the treatment of patients suffering from cholangiocarcinoma (bile duct cancer). This patient population has no approved treatment alternatives today […]

Initial clinical results from Phase I indicate that vaccination with fimaVacc enhances cellular immune responses

Posted on Sep 12, 2017

Oslo (Norway), 12 September 2017 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the first immune response results from the fimaVACC Phase I study in healthy volunteers indicate enhanced overall T-cell responses at tolerable dose levels. The clinical data cover more […]

Capital increase registered and listing of new shares

Posted on Sep 8, 2017

Oslo, 8 September 2017 – Reference is made to the stock exchange notice of 5 September 2017 by PCI Biotech Holding ASA (the “Company”) in respect of the issuance of 86,500 new shares following exercise of employee share options in the Company. The share capital increase resolved by the Board of Directors following the share […]